Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new randomized study sought to clarify results from previous studies that suggested there would be a benefit from such local treatment.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
Tucatinib fights breast cancer that spreads to the brain
Former Air Force senior master sergeant Sheila McGlown, 53, has metastatic breast cancer. She lives with her husband near St. Louis.
“In the era of targeted therapy, it is critical to know that a therapy is the right choice and is going to be effective.”
The efficacy of Nerlynx with capecitabine was investigated in a randomized, multicenter, open-label clinical trial in 621 people.
In both clinical trials, women whose cancers had spread to the brain were eligible to participate.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
Prestigious prize goes to researchers who identified B cells and T cells and others who invented the HER2 targeted cancer therapy Herceptin.
Black women, as well as those with Medicaid or no insurance, were less likely to receive surgery and more likely to die.
The decision to sign up for a clinical trial is not easy; there are risks for everything we do in terms of health and wellness.
Recent studies have shown that the disease has a unique biology—different from that of more common forms of breast cancer
Study shows six months of trastuzumab works as well as a full year.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.